小胰腺癌血清CA19-9测定及其临床意义

Detection and Clinical Significance of Serum CA19-9 for Small Pancreas Cancer

目的：明确血清CA19-9测定对小胰腺癌诊断的意义。方法：通过对86例胰腺癌患者血清CA19-9的检测，并对其中18例肿瘤直径≤2cm(小胰腺癌)患者进行B超、CT、MRI及ERCP检测。结果：结果表明小胰腺癌患者血清CA19-9的阳性率为61.1%，平均值为140.5u/ml，病理显示CA19-9阳性多见于病灶有转移的小胰腺癌病人。血清CA19-9的阳性与小胰腺癌的病程，部位无关。结论：CA19-9检测有助于对手术疗效的评价与术后随访的监测。MRI、ERCP对小胰腺癌诊断阳性率明显高于B超、CT。联合应用血清CA19-9、MRI、ERCP可达到早期诊断小胰腺癌的目的，而早期手术可降低死亡率，改善预后。

Objective: To determine the significance of serum CA19-9 for small pancreas cancer. Methods: The serum CA19-9 of 86 patients of pancreas cancer was detected. 18 patients of small pancreas cancer whose tumor diameter were less than 2 cm were received B ultrasound, CT, MRI and ERCP. Results: The serum CA19-9 positive rate was 61.1% in the patients of small pancreas cancer with its average value 140.5u/ml. The CA19-9 positive was common in the patient of small pancreas cancer with the lesion focus metastasis. There was no correlation between the serum CA19-9 and stage and tumor site of small pancreas cancer. Conclusion: The detection of serum CA19-9 might be helpful for the assessment of operative effect and supervision of follow-up after operation. The diagnostic positive rate of MRI and ERCP for small pancreas cancer should be higher than that of B ultrasound and CT. The combination detections of the serum CA19-9, MRI and ERCP could reach the purpose of early diagnosis. Early operation could reduce the mortality and improve the prognosis.